Purple Biotech (PPBT) Net Income towards Common Stockholders (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Net Income towards Common Stockholders of $86000.0 for Q1 2026, down 81.02% year-over-year from $453000.0 in Q1 2025, and down 99.63% quarter-over-quarter from $23.5 million in Q4 2025.
Purple Biotech (PPBT) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Net Income towards Common Stockholders for 13 consecutive years, with $86000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 81.02% year-over-year to $86000.0; the TTM figure through Mar 2026 stood at $26.0 million (up 560.91% YoY), while the FY2025 annual figure was -$26.4 million, down 264.45% from the prior year.
- Net Income towards Common Stockholders eased to $86000.0 in Q1 2026 per PPBT's latest filing, from $23.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $23.5 million in Q4 2025 and bottomed at $86000.0 in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged $4.4 million across 5 years, with a median of $3.8 million in 2024.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders slumped 91.51% — and 2025, when it jumped 5642.93%.
- Purple Biotech's Net Income towards Common Stockholders stood at $6.0 million in 2022, then retreated by 19.68% to $4.8 million in 2023, then plunged by 91.51% to $410000.0 in 2024, then surged by 5642.93% to $23.5 million in 2025, then sank by 99.63% to $86000.0 in 2026.
- Business Quant data shows PPBT's Net Income towards Common Stockholders at $86000.0 in Q1 2026, $23.5 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | -441,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86,000.00 |
| Dec 31, 2025 | 23.55 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 453,000.00 |
| Dec 31, 2024 | 410,000.00 |
| Sep 30, 2024 | 663,000.00 |
| Jun 30, 2024 | 2.41 Mn |
| Mar 31, 2024 | 3.78 Mn |
| Dec 31, 2023 | 4.83 Mn |
| Sep 30, 2023 | 5.04 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 4.88 Mn |
| Dec 31, 2022 | 6.01 Mn |
| Sep 30, 2022 | 4.82 Mn |
| Jun 30, 2022 | 3.56 Mn |
| Mar 31, 2022 | 7.30 Mn |
| Dec 31, 2021 | 8.21 Mn |
| Sep 30, 2021 | 3.15 Mn |
| Jun 30, 2021 | 3.64 Mn |